Back

PINK1 Expression as a Prognostic Biomarker in Glioblastoma Multiforme: An Observational Multicenter Study

Garcia Rairan, L. A.; Corpus Gutierrez, v.; Del castillo, m. a.; Riveros Castillo, W.; Saavedra Gerena, J.; Turizo Smith, A. D.; Arias Guatibonza, J.

2026-04-05 oncology
10.64898/2026.04.03.26350127 medRxiv
Show abstract

Introduction: Glioblastoma multiforme (GBM) remains the most lethal primary brain tumor with median survival of 14-15 months. Current prognostic markers inadequately stratify patient outcomes. PINK1 (PTEN-induced putative kinase 1), a mitochondrial kinase regulating mitophagy and cellular stress responses, has emerged as a promising prognostic candidate. Our preliminary analysis of 20 GBM cases demonstrated significant PINK1 expression with correlation to aggressive phenotypes (Turizo Smith et al., 2025). This multicenter study aims to prospectively validate PINK1 as a prognostic biomarker for survival and functional outcomes in a Latin American cohort. Methods and analysis: PINK1-GBM Colombia is a multicenter, observational cohort study across four tertiary hospitals in Bogota, Colombia (Hospital de Kennedy, Hospital El Tunal, Hospital Santa Clara and Hospital Universitario de la Samaritana). We will enroll at least 26-50 adults (18+ years) with newly diagnosed IDH-wild type GBM undergoing surgical resection. PINK1 expression will be quantified by immunohistochemistry (IHC) on formalin-fixed paraffin embedded (FFPE) tissue using standardized protocols. Primary outcomes: overall survival (OS) and progression-free survival (PFS). Secondary outcomes: functional status trajectories (KPS/ECOG). Follow-up extends 24 months with clinical, imaging (RANO 2.0), and telephone assessments. Survival analyses will employ Kaplan-Meier methods, log-rank tests, and Cox proportional hazards models adjusted for established prognostic factors. Ethics and dissemination: Approved by Universidad Nacional de Colombia Ethics Committee (Acta 001, February 5, 2026; Ref: 2.FM.1.002-CE-002-26), Subred Sur Occidente (P-AP-19-2025, July 11, 2025), and Subred Centro Oriente (CEI 067/2025, October 24, 2025). Conducted per Declaration of Helsinki and Colombian Resolution 8430/1993. Results will be disseminated via peer-reviewed publication, international conferences, and thesis submission.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 13%
14.4%
2
BMJ Open
554 papers in training set
Top 2%
10.1%
3
Neuro-Oncology Advances
24 papers in training set
Top 0.1%
8.4%
4
Journal of the Neurological Sciences
17 papers in training set
Top 0.1%
4.9%
5
Diagnostics
48 papers in training set
Top 0.3%
4.3%
6
Neuro-Oncology
30 papers in training set
Top 0.3%
3.6%
7
Brain and Behavior
37 papers in training set
Top 0.1%
3.6%
8
Neuropathology and Applied Neurobiology
14 papers in training set
Top 0.1%
3.6%
50% of probability mass above
9
Biology Methods and Protocols
53 papers in training set
Top 0.3%
3.6%
10
Acta Neuropathologica Communications
81 papers in training set
Top 0.3%
2.9%
11
Cancers
200 papers in training set
Top 2%
2.7%
12
Frontiers in Oncology
95 papers in training set
Top 2%
2.6%
13
Molecular Oncology
50 papers in training set
Top 0.2%
2.6%
14
FEBS Open Bio
29 papers in training set
Top 0.1%
2.4%
15
Journal of Clinical Medicine
91 papers in training set
Top 3%
1.9%
16
Scientific Reports
3102 papers in training set
Top 53%
1.9%
17
Cells
232 papers in training set
Top 3%
1.3%
18
Cancer Letters
32 papers in training set
Top 0.4%
1.3%
19
International Journal of Molecular Sciences
453 papers in training set
Top 11%
1.2%
20
PeerJ
261 papers in training set
Top 11%
0.9%
21
Computers in Biology and Medicine
120 papers in training set
Top 3%
0.9%
22
NMR in Biomedicine
24 papers in training set
Top 0.3%
0.9%
23
Frontiers in Molecular Biosciences
100 papers in training set
Top 4%
0.9%
24
Interface Focus
14 papers in training set
Top 0.2%
0.9%
25
Annals of Oncology
13 papers in training set
Top 1.0%
0.7%
26
Biomolecules
95 papers in training set
Top 2%
0.7%
27
Clinical Cancer Research
58 papers in training set
Top 2%
0.7%
28
Brain, Behavior, & Immunity - Health
27 papers in training set
Top 0.6%
0.7%
29
JCO Precision Oncology
14 papers in training set
Top 0.4%
0.7%
30
Frontiers in Neuroscience
223 papers in training set
Top 9%
0.6%